Compare AMP & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMP | ZTS |
|---|---|---|
| Founded | 1894 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.1B | 54.8B |
| IPO Year | 2008 | 2012 |
| Metric | AMP | ZTS |
|---|---|---|
| Price | $463.86 | $121.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $560.20 | $156.20 |
| AVG Volume (30 Days) | 689.1K | ★ 3.9M |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | 1.35% | ★ 1.73% |
| EPS Growth | 9.77 | ★ 10.05 |
| EPS | ★ 36.28 | 6.02 |
| Revenue | ★ $18,911,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | $1.71 | $5.69 |
| Revenue Next Year | $4.38 | $4.81 |
| P/E Ratio | ★ $13.02 | $20.32 |
| Revenue Growth | ★ 5.49 | 2.28 |
| 52 Week Low | $396.14 | $115.25 |
| 52 Week High | $550.18 | $177.00 |
| Indicator | AMP | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 38.09 |
| Support Level | $463.00 | $117.42 |
| Resistance Level | $515.17 | $130.52 |
| Average True Range (ATR) | 12.64 | 3.28 |
| MACD | -0.61 | -0.79 |
| Stochastic Oscillator | 38.87 | 22.33 |
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating income from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third key segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.